therapies with the potential to improve the treatment of cancer . over the past decade we have established a broad development platform laying the foundation for our continued efforts to bring new therapies for cancer to patients in need . to date three medicines discovered at exelixis have received regulatory approval to treat different types of cancer . we are steadfast in our commitment to excellence in all aspects of our business and are dedicated to improving the care of and outcomes for patients in need of new treatment options . stock nasdaq exel oct 14 2016 4 00pm edt price 11.32 0.59 volume 6 418 212 shares 20 minute delay exelixis in the news oct 10 2016 exelixis announces positive results from phase 2 cabosun trial of cabozantinib versus sunitinib in previously untreated advanced renal cell carcinoma presented at esmo 2016 oct 7 2016 exelixis announces genentech presentation of preliminary phase 1b results for the combination of cobimetinib vemurafenib and atezolizumab at esmo 2016 congress oct 7 2016 exelixis announces phase 1 trial results for cabozantinib in combination with nivolumab in advanced genitourinary tumors oct 3 2016 exelixis and ipsen to host investor and media briefing to discuss data presented at the esmo 2016 congress more news investor briefing at esmo 2016 congress exelixis management and invited guests discussed new data for cabozantinib being presented at esmo including the results of the cabosun phase 2 randomized trial . we apologize for any connectivity issues you experienced with the live stream but the replay and related materials are now available . see the video replay hear the audio only replay download slides fda approval on april 25 2016 the united states food and drug administration approved a new medicine from exelixis cabometyx . view press release view investor analyst webcast about usmanagement board of directors collaborations locations contact us medicines pipelinecabozantinib cobimetinib xl888 partnered compounds clinical trialsexelixis clinical trials national cancer institute sponsored trials investigator sponsored trials faqs about clinical trials medical information investors & mediamanagement and board corporate governance stock information analyst coverage earnings estimates earnings ratings annual reports sec filings press releases event calendar media resources information request investor faqs contact ir responsibilityethics and compliance careersjob opportunities search this site exelixis inc. 2016 website design hane chow inc. privacy terms of use